J

Jacques DUMAS

Venture Partner
💼 Partner bei AdBio Partners →
Über

Jacques Dumas joined AdBio Partners in 2025 as a Venture Partner. He has over 30 years of experience in drug discovery and development. He is a co-inventor of two Oncology drugs, Nexavar® and Stivarga®, and played a key role in the registration of Xerava®, a broad-spectrum antibacterial. Jacques has been working with Adbio as a consultant since 2023. He is currently Chief Scientific Officer (CSO) at AiCuris where he oversees non-clinical development. Between 2020 and 2024 Jacques worked at Arrakis, a company dedicated to the discovery of small molecules targeting RNA, first as SVP then CSO. From 2015 to 2019, Jacques was CSO at Tetraphase, a publicly traded company focused on fully synthetic tetracycline antibacterials where he supported the early pipeline and the US/EU eravacycline approvals. Before joining Tetraphase, Jacques was CSO at Idenix (acquired by Merck in 2014) working on liver-targeted nucleosides for the treatment of Hepatitis C. Between 1992 and 2013, Jacques held various R&D roles at AstraZeneca and Bayer, both in Europe and the USA.

Schwerpunkte

Oncology, BioTech

Region

📍 Ansässig in Paris, France

Verifizierte Kontakte & Outreach Agenten

Direktes E-Mail-Muster

[email protected] | [email protected]

KI Outreach Agenten Pitch Writer

Erstelle personalisierte Anschreiben basierend auf den genauen Investitionskriterien...

Direkten Partnerkontakt freischalten

Erhalte Zugriff auf verifizierte Kontakte und nutze unseren Outreach Composer, um Anschreiben in Sekundenschnelle zu entwerfen.

Über GRID kontaktieren

100% kostenloses Konto · Start in 1 Klick